Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.
Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.
复制标题
DOI:
10.1002/hed.21455
复制
发表时间:
2011-03
影响因子:
2.9
通讯作者:
Myers, Jeffrey N.
中科院分区:
文献类型:
--
作者:
Sano, Daisuke;Fooshee, David R.;Zhao, Mei;Andrews, Genevieve A.;Frederick, Mitchell J.;Galer, Chad;Milas, Zvonimir L.;Morrow, Phuong Khanh H.;Myers, Jeffrey N.
关键词:
We investigated the effects of vandetanib, an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2) and epidermal growth factor receptor (EGFR), alone and in combination with paclitaxel in an orthotopic mouse model of human head and neck squamous cell carcinoma (HNSCC). The in vitro effects of vandetanib (ZACTIMA™) were assessed in two HNSCC cell lines on cell growth, apoptosis, and receptor and downstream signaling morecule expression and phosphorylation levels. We assessed in vivo effects of vandetanib and/or paclitaxel by measuring tumor cell apoptosis, endothelial cell apoptosis, microvessel density, tumor size, and animal survival. In vitro, vandetanib inhibited the phosphorylation of EGFR and its downstream targets in HNSCC cells and inhibited proliferation and induced apoptosis of HNSCC cells and extended survival and inhibited tumor growth in nude mice orthotopically injected with human HNSCC. Vandetanib has the potential to be a novel molecular targeted therapy for HNSCC.
登录
查看更多内容
影响因子:
254.7
作者:
Jemal, Ahmedin;Siegel, Rebecca;Thun, Michael J.
通讯作者:
Thun, Michael J.
影响因子:
6.4
作者:
Grant, DS;Williams, TL;Dicker, AP
通讯作者:
Dicker, AP
影响因子:
50.5
作者:
Morelli, M. P.;Cascone, T.;Ciardiello, Fortunato
通讯作者:
Ciardiello, Fortunato
影响因子:
11.2
作者:
Kim, SJ;Uehara, H;Fidler, IJ
通讯作者:
Fidler, IJ
影响因子:
2.3
作者:
Conrad, Claudius;Ischenko, Ivan;Bruns, Christiane J.
通讯作者:
Bruns, Christiane J.